- Home
- GCTK vs CMND Comparison
GCTK vs CMND Comparison
Compare GCTK & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GCTK | CMND |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 2 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.5M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GCTK | CMND |
|---|---|---|
| Price | $0.50 | $2.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.9M | 1.5M |
| Earning Date | 05-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.65 | N/A |
| Revenue | ★ $589,462.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.09 | $0.07 |
| 52 Week High | $15.90 | $3.25 |
Technical Indicators
Market Signals| Indicator | GCTK | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 36.39 | 74.58 |
| Support Level | N/A | $0.99 |
| Resistance Level | $1.02 | $2.76 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | -0.02 | 0.19 |
| Stochastic Oscillator | 9.60 | 87.34 |
Price Performance
Historical ComparisonAbout GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.